Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Novartis is reimagining medicine to improve and extend peoples lives. As a leadin...
Novartis is reimagining medicine to improve and...
Allakos is a clinical-stage company developing therapeutic antibodies that selecti...
Allakos is a clinical-stage company developing ...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company that...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a gl...
Headquartered in Waltham, Massachusetts, we develop and deliver innovative medicin...
Headquartered in Waltham, Massachusetts, we dev...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing comme...
BioDelivery Sciences International, Inc. (NASDA...
Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...
Adaptimmune is a leader in TCR T-cell therapy, ...
Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...
Neoleukin is a biopharmaceutical company creati...
Join the National Investor Network and get the latest information with your interests in mind.